Supplemental material Figure 1. 2017 CONSORT checklist of information to include when reporting a randomized trial assessing non-pharmacologic treatments (NPTs)*. Modifications of the extension appear in italics and blue.

Section/Topic Item	Checklist item no.	CONSORT item	Extension for NPT trials
Title and abstract			
	1a	Identification as a randomized trial in the title	
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	*Refer to CONSORT extension for abstracts for NPT trials*
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	
	2b	Specific objectives or hypotheses	
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	When applicable, how care providers were allocated to each trial group
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	When applicable, eligibility criteria for centers and for *care providers*
	4b	Settings and locations where the data were collected	

Section/Topic Item	Checklist item no.	CONSORT item	Extension for NPT trials
Interventions *†	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	Precise details of both the experimental treatment and comparator
	5a		Description of the different components of the interventions and, when applicable, description of the procedure for tailoring the interventions to individual participants.
	5b		Details *of whether and* how the interventions were standardized.
	5c.		Details *of whether and* how adherence of care providers to the protocol was assessed or enhanced
	5d		*Details of whether and how adherence of participants to interventions was assessed or enhanced*
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	
	6b	Any changes to trial outcomes after the trial commenced, with reasons	
Sample size	7a	How sample size was determined	When applicable, details of whether and how the clustering by care providers or centers was addressed

Section/Topic Item	Checklist item no.	CONSORT item	Extension for NPT trials
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomization:			
- Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomization; details of any restriction (such as blocking and block size)	
- Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	
- Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	If done, who was blinded after assignment to interventions (e.g., participants, care providers, *those administering co-interventions*, those assessing outcomes) and how
	11b	If relevant, description of the similarity of interventions	
	11c		*If blinding was not possible, description of any attempts to limit bias*

Section/Topic Item	Checklist item no.	CONSORT item	Extension for NPT trials
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	When applicable, details of whether and how the clustering by care providers or centers was addressed
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome	The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider or in each center
	13b	For each group, losses and exclusions after randomization, together with reasons	
	13c		*For each group, the delay between randomization and the initiation of the intervention*
	new		Details of the experimental treatment and comparator as they were implemented
Recruitment	14a	Dates defining the periods of recruitment and follow-up	
	14b	Why the trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group.

Section/Topic Item	Checklist item no.	CONSORT item	Extension for NPT trials
Numbers analyzed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
Harms	19	All-important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

Section/Topic Item	Checklist item no.	CONSORT item	Extension for NPT trials
Generalizability	21	Generalizability (external validity, applicability) of the trial findings	Generalizability (external validity) of the trial findings according to the intervention, comparators, patients, and care providers and centers involved in the trial
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
Other information			
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	

**Additions or modifications to the 2010 CONSORT checklist. CONSORT = Consolidated Standards of Reporting Trials*

†The items 5, 5a, 5b, 5c, 5d are consistent with the Template for Intervention Description and Replication (TIDieR) checklist